menu search

Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023

Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater than $730 million in cash and equivalents at 6/30/23; extended cash runway into second half of 2027- -New clinical trials of MORF-057 in Crohn’s disease and MORF-088 in […] The post Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023 appeared first on ForexTV... Read More
Posted: Aug 3 2023, 11:05
Author Name: forextv
Views: 102157

Search within

Pages Search Results: